Investigational drug · Phase 2
HP-002
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for B-Cell Non-Hodgkin Lymphoma.
Phase 2Last checked: Nov 19, 2026Latest source record: Jun 22, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "HP-002"
First trial start
2026
Jun 26, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "HP-002", any sponsor or status.
Conditions studied
As listed on its trial records.
- B-Cell Non-Hodgkin Lymphoma
Approved drugs for the same conditions: Lymphoma (non-Hodgkin) · Hodgkin lymphoma · Hematology and blood cancers
Largest trials
Live from ClinicalTrials.gov: studies naming "HP-002" as an intervention, largest first.
- A First-in-Human Study of HP-002 for Relapsed or Refractory B-Cell Non-Hodgkin LymphomaNot yet recruiting
Shanghai Helioson Pharmaceutical Co., Ltd.Industry
NCT07658352 · 114 participants (planned) · Start Jun 26, 2026 · Primary completion Jun 26, 2029
Drug: HP-002 · For: B-Cell Non-Hodgkin Lymphoma
Sites: Guangzhou, China
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for B-Cell Non-Hodgkin Lymphoma
- SurovatamigAZD0486, TNB-486Phase 39 trials
AstraZeneca · B-cell Non-Hodgkin Lymphoma, Large B-cell Lymphoma, Untreated Follicular Lymphoma
- AZD4512Phase 21 trial
AstraZeneca · B-cell Non-Hodgkin Lymphoma
- DS3790aPhase 21 trial
Daiichi Sankyo · Hematological Malignancies, B-cell Non-Hodgkin Lymphoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.